Please assess the completion status of the following clinical trial:

Trial Title: Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female greater than or equal to 18 years.~* Histologically confirmed breast adenocarcinoma with incurable progressing local-regional or metastatic.~* ER and/or PR positivity of primary and/or secondary tumor.~* Patients must have measurable or evaluable disease.~* Evidence of disease progression or relapse while on or less than 6 months off aromatase inhibitors or tamoxifen either in adjuvant or first line metastatic setting.~* Postmenopausal~* Patients may have received up to one prior chemotherapy regimen for stage IV breast cancer. Prior chemotherapy in the adjuvant and/or neoadjuvant setting is permitted. Chemotherapy must be finished at least 2 weeks prior to enrollment.~* ECOG performance status \<2~* Fasting cholesterol ≤300 mg/dL OR ≤7.75 mmol/LAND fasting triglycerides ≤ 2.5 x ULN despite appropriate treatment.~* Patients must have adequate organ function as defined by the protocol.~* Stratification 1:~  * HER2 positive in the primary or secondary tumor tissue~ * Prior trastuzumab therapy is allowed but NOT required. However, trastuzumab should be discontinued at least 3 weeks prior to enrollment.~* Stratification 2:~  * HER2 negative in the primary or secondary tumor tissue~Exclusion Criteria:~* Patients receiving any other investigational agents.~* Prior exposure to lapatinib, everolimus, or other mTOR inhibitors.~* History of allergic reactions or hypersensitivity to compounds similar to everolimus, lapatinib, or letrozole.~* Patients who have any severe and/or uncontrolled medical conditions that could affect their participation such as:~  * Left ventricular ejection fraction (LVEF) \< 50%~ * Unstable angina, symptomatic congestive heart failure, myocardial infarction within 6 months, serious uncontrolled cardiac arrhythmia or any other clinically significant cardiac disease.~ * Severely impaired lung function as defined as spirometry and DLCO that is 50% of the normal predicted value and/or O2 saturation that is ≤ 88% at rest on room air.~ * Uncontrolled diabetes~ * Active or uncontrolled severe infection~* Patients with QTc interval \> 0.47 seconds.~* Significant chronic or acute gastrointestinal disorder with diarrhea as a major symptom.~* Prior exposure to more than 360 mg/m2 doxorubicin, more than 120 mg/m2mitoxantrone, or more than 90 mg/m2idarubicin, or elevated baseline cardiac troponin I.~* Patients with active CNS metastasis and/or carcinomatous meningtitis. However, patients with CNS metastasis who have completed a therapy and are clinically stable for 3 weeks as defined as: (1) no evidence of new or enlarging CNS metastasis and (2) off steroids and/or anticonvulsants.~* Patient is known to be HIV, Hepatitis B, or Hepatitis C-positive (these tests are not required).~* Patients with current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease).~* Patients with INR ≥ 2 or PTT ≥ 2 x upper normal limit.~* Previous or current systemic malignancy other than breast cancer within the past 3 years other than carcinoma in situ of the cervix or basal/squamous carcinoma of the skin.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HER2-positive or negative (Type: EXPERIMENTAL): Lapatinib 1,500 mg/day + letrozole 2.5 mg/day until progression followed by everolimus 5 mg/day + letrozole 2.5 mg/day + lapatinib 1,250 mg/day.

Based on this trial design, predict the completion outcome and termination type (if applicable).